- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02849288
Bigfoot Biomedical Clinical Research Center (CRC) Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93111
- William Sansum Diabetes Research Institute
-
Stanford, California, United States, 94305
- Stanford University
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Barbara Davis Center for Childhood Diabetes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Insulin dependent type 1 diabetes (T1D) for at least one year
- Age ≥ 7 years of age
- Weight ≥ 26 kg
- HbA1c <10%
- Total BASAL insulin dose (24 hour cumulative total) that is ≥ 5 units and ≤ 72 units per day
Insulin regimen stable on either multiple daily insulin injections (MDI) or insulin infusion pump therapy for ≥ 6 months. Regimen must include basal insulin and the use of a rapid acting analog insulin to cover meals (e.g., Novolog, Humalog or Apidra)
- For participants on MDI, basal insulin must be either once daily Lantus (Glargine) or once daily Levemir (Detemir). The once daily basal insulin dose must be administered in the evening or at bedtime
- Able to engage in at least 60 minutes of moderate exercise if ≥ 12 years of age (e.g., walking or biking) and if ≥ 7 and < 12 years of age moderate activity (e.g., walking or active play)
- Willing and able to refrain from use of any medication containing acetaminophen during participation in the study (from the time of consent until study exit)
- Willing and able to use Humalog insulin during the CRC admission
- Able to speak and read English
Exclusion Criteria:
- Females who are sexually active and able to conceive will be excluded if they are not currently using or agree to continue use for the duration of the study an effective method of contraception as determined by investigator
Females who are pregnant or intending to become pregnant during participation in the trial
• Females who are capable of childbearing must have a negative pregnancy test at the time of the screening visit and the pregnancy test must be repeated at enrollment if it was done > 14 days prior
- Presence of any condition that in the opinion of the investigator impairs the participant's ability to use the system (e.g.,visual impairment that interferes with ability to read the display)
- Unable or unwilling to use study devices and follow study procedures including the meal and exercise/ activity challenges in the CRC.
- A current condition that would prevent the use of a study devices, including blood glucose meter (BGM), continuous glucose monitoring (CGM) or insulin pump (CSII)
Current participation within the last 60 days in another clinical research study that involves an intervention
• Participation in research studies involving data collection only is not an exclusion (e.g.,T1D Exchange Registry)
- Anticoagulant therapy other than aspirin
- Severe hypoglycemia resulting in seizure OR loss of consciousness within 30 days prior to enrollment
- Diabetic ketoacidosis (DKA) requiring treatment in a healthcare facility within 30 days prior to enrollment
- Current use (defined as within the last 3 months) of any medication intended to lower glucose other than insulin (e.g., use of Metformin, Liraglutide, would be exclusions)
Current use (defined as within the last 3 months) of any medication that according to the dose, frequency, and route of administration may result in hyperglycemia in the investigator's judgment (e.g., current use of oral steroids)
• Regular use of inhaled or intranasal steroids is permitted
Presence of significant renal disease as evidenced by the presence of any of the following:
- Current dialysis therapy
- Serum creatinine of ≥ 2.0 mg/dL within 30 days of enrollment
For screening purposes, serum creatinine levels will be tested in participants who meet any of the following criteria:
- A≥10 year history of T1D
- Are ≥ 45 years of age
- Presence or history of clinically significant cardiovascular disease (e.g., myocardial infarction, pacemaker, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, atrial or ventricular fibrillation, treatment for arrhythmia, stable or unstable angina, episode of chest pain of cardiac etiology with associated ECG changes or positive stress test/ cardiac catheterization, congestive heart failure, or cerebrovascular event)
ECG findings that indicate participation in the planned exercise/ activity session would be contraindicated as determined by trained personnel at the respective clinical center(s)
• For screening purposes, ECGs must be completed within 30 days of enrollment in participants who meet any of the following criteria:
- A ≥ 10 year history of T1D and ≥ 20 years of age
- Are ≥ 45 years of age
- History of adrenal insufficiency
- A diagnosis of gastroparesis or impaired gastric motility that required pharmacological or surgical treatment
- Celiac Disease (CD) diagnosed < 12 months ago or CD that is currently inadequately treated as determined by the investigator
- Current alcohol abuse or eating disorder as determined by the investigator
- Use or abuse of controlled substances without a prescription in the 6 months prior to enrollment
- History of hemoglobinopathy, sickle cell disease, or blood dyscrasia; blood transfusion within 3 months of enrollment
- Hematocrit that is above or below the normal reference range of the lab used within 14 days of enrollment
- Presence or history of any medical or psychiatric condition, or the use of any medication or therapy, that in the opinion of the investigator may be a contraindication to participation in the study
- Unstable hypertension, thyroid disease, or depression as evidenced by an adjustment in therapy for the condition within the last 2 months, or as determined by investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
|
Automated Insulin Delivery System
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate performance of the algorithm/ system commanded delivery of insulin in response to glucose trends from the CGM. in an effort to avoid hypoglycemia and hyperglycemia.
Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
Annotated graphs will be used to assess this outcome.
|
Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
Assessment of safety outcomes and serious adverse events and device related adverse effects.
Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measures of glycemic control
Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
Additional measures include but are not limited to, mean glucose (arithmetic and geometric), Glucose variability as assessed by coefficient of variation and standard deviation (arithmetic and geometric).
Percentage of time spent below or above glucose threshold levels.
|
Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
System functionality as evidenced by the availability of CGM data
Time Frame: Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
Includes but is not limited to the percentage of time CGM values were available for individual participants and for all participants pooled.
|
Data will be evaluated upon completion of an individual participant (data collected over approximately 48 hours of use), upon completion of each age cohort, and upon completion of the trial
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TST-10025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)
-
Bigfoot Biomedical Inc.Jaeb Center for Health ResearchEnrolling by invitation
-
Second Xiangya Hospital of Central South UniversityRecruitingDiabetes | Type1diabetesChina
-
Akdeniz UniversityRecruitingSelf Efficacy | Adolescent Behavior | type1diabetesTurkey
-
Region Jönköping CountyLinkoeping University; Region Östergötland; Uppsala County Council, Sweden; Medical... and other collaboratorsRecruitingType 2 DiabetesSweden
-
HealthPartners InstituteAbbott Diabetes CareCompletedDiabetes | Glucose Variability | CGMUnited States
-
HealthPartners InstituteAbbott Diabetes CareCompletedGlucose Variability | CGM | NonDiabetesUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Enrolling by invitationFamilial Adenomatous PolyposisNetherlands
-
University of Massachusetts, WorcesterCompletedObesity | Schizophrenia | Schizoaffective Disorder | Vitamin D Deficiency | PsychosisUnited States
-
Methodist Health SystemWithdrawnDiabetes | Liver Transplant; Complications | Kidney Transplant FailureUnited States
-
Muğla Sıtkı Koçman UniversitySuspendedVentilator-associated Pneumonia (VAP)Turkey